Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.440
+0.050 (3.60%)
At close: Dec 20, 2024, 4:00 PM
1.410
-0.030 (-2.08%)
After-hours: Dec 20, 2024, 5:00 PM EST
Outlook Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
24
Market Cap
34.06M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 996.89M |
Cumberland Pharmaceuticals | 36.79M |
Precision Optics Corporation | 18.98M |
Surrozen | 10.00M |
NEXGEL | 6.73M |
Moolec Science | 5.63M |
Marker Therapeutics | 5.40M |
Incannex Healthcare | 86.00K |
OTLK News
- 8 days ago - Outlook Therapeutics® Streamlines Operations - GlobeNewsWire
- 17 days ago - Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 18 days ago - Outlook Therapeutics® Announces Executive Leadership Transition - GlobeNewsWire
- 24 days ago - Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? - Benzinga
- 24 days ago - Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 3 months ago - Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewsWire